LU90843I2 - Starlix-nateglinide et ses d-riv-s pharmaceutiquement acceptables - Google Patents

Starlix-nateglinide et ses d-riv-s pharmaceutiquement acceptables

Info

Publication number
LU90843I2
LU90843I2 LU90843C LU90843C LU90843I2 LU 90843 I2 LU90843 I2 LU 90843I2 LU 90843 C LU90843 C LU 90843C LU 90843 C LU90843 C LU 90843C LU 90843 I2 LU90843 I2 LU 90843I2
Authority
LU
Luxembourg
Prior art keywords
crystals
solvent
compound
starlix
nateglinide
Prior art date
Application number
LU90843C
Other languages
English (en)
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27169694&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90843(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of LU90843I2 publication Critical patent/LU90843I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU90843C 1991-07-30 2001-09-28 Starlix-nateglinide et ses d-riv-s pharmaceutiquement acceptables LU90843I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP18969691 1991-07-30
JP19945391 1991-08-08
CA002114678A CA2114678C (fr) 1991-07-30 1994-02-01 Cristaux de n-(trans-4-isopropylcyclohexylcarbonyl)- d-phenylalanine et methodes pour les preparer

Publications (1)

Publication Number Publication Date
LU90843I2 true LU90843I2 (fr) 2002-02-04

Family

ID=27169694

Family Applications (2)

Application Number Title Priority Date Filing Date
LU90843C LU90843I2 (fr) 1991-07-30 2001-09-28 Starlix-nateglinide et ses d-riv-s pharmaceutiquement acceptables
LU90846C LU90846I2 (fr) 1991-07-30 2001-10-03 Starlix-nateglinide et ses d-riv-s pharmaceutiquement acceptables

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU90846C LU90846I2 (fr) 1991-07-30 2001-10-03 Starlix-nateglinide et ses d-riv-s pharmaceutiquement acceptables

Country Status (11)

Country Link
US (1) US5488150A (fr)
EP (1) EP0526171B1 (fr)
JP (1) JP2508949B2 (fr)
AT (1) ATE149483T1 (fr)
BR (1) BR1100807A (fr)
CA (1) CA2114678C (fr)
DE (2) DE69217762T2 (fr)
DK (1) DK0526171T3 (fr)
ES (1) ES2100291T3 (fr)
LU (2) LU90843I2 (fr)
NL (1) NL300063I2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2271865C (fr) 1996-11-15 2003-10-14 Ajinomoto Co., Inc. Preparation en comprimes
GB9713730D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CA2673615C (fr) 2000-01-21 2013-07-16 Novartis Ag Combinaisons comprenant des inhibiteurs de la dipeptidylpeptidase- iv et des agents antidiabetiques
PE20020617A1 (es) 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
KR100819358B1 (ko) 2000-10-18 2008-04-04 아지노모토 가부시키가이샤 나테글리니드 결정의 제조방법
DK1334962T3 (da) * 2000-10-18 2007-12-10 Ajinomoto Kk Fremgangsmåder til fremstilling af acylphenylalanin
SI1334721T1 (sl) * 2000-10-24 2009-08-31 Ajinomoto Kk Hidrofilni farmacevtski pripravki, ki vsebujejo nateglinid
ES2307653T3 (es) * 2000-10-24 2008-12-01 Ajinomoto Co., Inc. Preparaciones que contienen nateglinida.
AU2001296001A1 (en) * 2000-10-24 2002-05-06 Ajinomoto Co., Inc. Process for producing b-form nateglinide crystal
AR035425A1 (es) * 2001-01-30 2004-05-26 Teijin Ltd Cristal de diclorhidrato del acido 3-(3-amidinofenil)-5-[({[1-(iminoetil)-4-piperidil]metil}amino)metil]benzoico y proceso para prepararlo
WO2003022251A1 (fr) * 2001-09-12 2003-03-20 Alembic Limited Nouvelle forme de cristal stable de n-(trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanine et procede de preparation correspondant
WO2003076393A1 (fr) * 2002-03-11 2003-09-18 Novartis Ag Sels de nateglinide
WO2003087039A1 (fr) * 2002-04-15 2003-10-23 Ajinomoto Co., Inc. Nouveau cristal de nateglinide
JP4615866B2 (ja) * 2002-04-15 2011-01-19 ノバルティス アーゲー Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
KR20040111490A (ko) * 2002-04-29 2004-12-31 바이오콘 리미티드 새로운 형태의 ｎ－（트랜스－4－이소프로필사이클로헥실카보닐）－ｄ－페닐알라닌
US6861553B2 (en) * 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
WO2004005240A1 (fr) * 2002-07-03 2004-01-15 Teva Pharmaceutical Industries Ltd. Procede de preparation de nateglinide et de ses intermediaires
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
US7148376B2 (en) * 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) * 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20040077725A1 (en) * 2002-08-28 2004-04-22 Dr. Reddy's Laboratories Limited Crystalline form of N-(trans-4-isopropylcyclohexane carbonyl)-D-phenylalanine and process for preparation thereof
JPWO2004074330A1 (ja) * 2003-02-18 2006-06-01 コニシ株式会社 硬化性樹脂、その製造方法及び硬化性樹脂組成物
HU227073B1 (hu) 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
CN1950331A (zh) * 2004-05-07 2007-04-18 特瓦制药工业有限公司 那格列奈的多晶型物
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
BRPI0616077B8 (pt) 2005-09-14 2021-05-25 Takeda Pharmaceuticals Co composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
WO2007119580A1 (fr) * 2006-03-31 2007-10-25 Ajinomoto Co., Inc. Procede de production d'un compose chlorure d'acide carboxylique
WO2008068615A1 (fr) * 2006-12-06 2008-06-12 Pfizer Inc. Formes cristallines de l'acide (3s)-3-[n-(n'-(2-tert-butyphényl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tétrafluorophénoxy)-4-oxopentanoïque
SG175925A1 (en) 2009-05-15 2011-12-29 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
UY32660A (es) 2009-05-28 2010-12-31 Novartis Ag Derivados aminobutricos sustituidos como inhibidores de neprilisina
MY156270A (en) 2009-05-28 2016-01-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
DK2531501T3 (en) 2010-02-03 2014-02-24 Takeda Pharmaceutical APOPTOSESIGNALREGULERENDE KINASE 1 inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
MA38330B1 (fr) 2013-02-14 2016-09-30 Novartis Ag Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
WO2015013169A2 (fr) 2013-07-25 2015-01-29 Novartis Ag Bioconjugués de polypeptides d'apeline synthétiques
WO2015013168A1 (fr) 2013-07-25 2015-01-29 Novartis Ag Polypeptides cycliques pour le traitement de l'insuffisance cardiaque
CA2972871A1 (fr) 2015-01-23 2016-07-28 Novartis Ag Conjugues d'acides gras de l'apeline synthetique presentant une demi-vie amelioree
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US196222A (en) * 1877-10-16 Improvement in belt-tighteners
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤

Also Published As

Publication number Publication date
NL300063I2 (nl) 2002-02-01
US5488150A (en) 1996-01-30
DE10199058I1 (de) 2002-01-24
DE69217762T2 (de) 1997-10-09
EP0526171B1 (fr) 1997-03-05
EP0526171A3 (en) 1993-05-05
ES2100291T3 (es) 1997-06-16
BR1100807A (pt) 1999-12-28
DK0526171T3 (da) 1997-08-25
CA2114678C (fr) 1999-04-27
JPH05208943A (ja) 1993-08-20
NL300063I1 (nl) 2001-12-01
ATE149483T1 (de) 1997-03-15
DE10199058I2 (de) 2006-04-27
LU90846I2 (fr) 2002-02-04
JP2508949B2 (ja) 1996-06-19
EP0526171A2 (fr) 1993-02-03
CA2114678A1 (fr) 1995-08-02
DE69217762D1 (de) 1997-04-10

Similar Documents

Publication Publication Date Title
LU90843I2 (fr) Starlix-nateglinide et ses d-riv-s pharmaceutiquement acceptables
FI102069B (fi) Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmist amiseksi
DE69429774D1 (de) Magnesium-omeprazol
DE69112463D1 (de) Vorrichtung zur Herstellung von Monokristallen nach dem Czochralski-Verfahren.
ES2132284T3 (es) Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa.
NZ234672A (en) N-(1,2,3,4-tetrahydro-9-acridinyl)amide and carbamate derivatives and pharmaceutical compositions
DK0400522T3 (da) Fremgangsmåde til fremstilling af mikroniserede bionedbrydelige partikler
FI883961A (fi) Farmaceutiskt nyttig polymorfisk modifikation av buspiron.
BR9707004A (pt) Composto processo para preparar o mesmo composição farmacêutica utilização do composto e processos para tratamento de doenças do sistema endocinológico e para a manufatura de um medicamento
ES2100177T3 (es) Compuestos de cefalosporina y su produccion.
SE8700212L (sv) Forfarande for framstellning av hns ii
YU48634B (sh) Postupak za dobijanje 6-(supstituisanih aminopropionil) derivata forskolina i jedinjenja koja se dobijaju ovim postupkom
FI102372B1 (fi) Menetelmä karbamyylijohdannaisen kiteisen muodon valmistamiseksi
FI102537B (fi) Dehalogenointimenetelmä 3-aroyyli-2-oksindoli-1-karboksiamidien valmis tamiseksi
DE69012845D1 (de) Exo-3'-4'-O-benzyliden-3"-demethylchartreusin und seine Salze.
PT94243A (pt) Processo para preparacao de inibidores beta-lactamicos de elastase
CA1262906C (fr) 3-(2-furoyl)-5-alcoxycarbonyl-2,6-dimethyl-4- (2-nitrophenyl)-1,4-dihydropyridines, antagonistes pour le calcium
NO834759L (no) Fremgangsmaate ved fremstilling av nye 6alfa-methylprednisolonderivater
JPS55153753A (en) New synthesis of 5-halogeno-2-methylaminobenzophenone
TH11174EX (th) อนุพันธ์ของพิเพอดิลอกซิ-ไอซอกซาโซล,การเตรียมสารเหล่านั้นและการใช้ในการรักษา